Yaghjyan Lusine, Heng Yujing J, Baker Gabrielle M, Bret-Mounet Vanessa, Murthy Divya, Mahoney Matt B, Mu Yi, Rosner Bernard, Tamimi Rulla M
Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, FL, United States.
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
Front Med (Lausanne). 2022 Dec 14;9:1040061. doi: 10.3389/fmed.2022.1040061. eCollection 2022.
The data on the expression of stem cell markers CD44, CD24, and ALDH1A1 in the breast tissue of cancer-free women is very limited and no previous studies have explored the agreement between pathologist and computational assessments of these markers. We compared the immunohistochemical (IHC) expression assessment for CD44, CD24, and ALDH1A1 by an expert pathologist with the automated image analysis results and assessed the homogeneity of the markers across multiple cores pertaining to each woman.
We included 81 cancer-free women (399 cores) with biopsy-confirmed benign breast disease in the Nurses' Health Study (NHS) and NHSII cohorts. IHC was conducted with commercial antibodies [CD44 (Dako, Santa Clara, CA, USA) 1:25 dilution; CD24 (Invitrogen, Waltham, MA, USA) 1:200 dilution and ALDH1A1 (Abcam, Cambridge, United Kingdom) 1:300 dilution]. For each core, the percent positivity was quantified by the pathologist and Definiens Tissue Studio. Correlations between pathologist and computational scores were evaluated with Spearman correlation (for categorical positivity: 0, >0-<1, 1-10, >10-50, and >50%) and sensitivity/specificity (for binary positivity defined with 1 and 10% cut-offs), using the pathologist scores as the gold standard. Expression homogeneity was examined with intra-class correlation (ICC). Analyses were stratified by core [normal terminal duct-lobular units (TDLUs), benign lesions] and tissue type (epithelium, stroma).
Spearman correlation between pathologist and Definiens ranged between 0.40-0.64 for stroma and 0.66-0.68 for epithelium in normal TDLUs cores and between 0.24-0.60 for stroma and 0.61-0.64 for epithelium in benign lesions. For stroma, sensitivity and specificity ranged between 0.92-0.95 and 0.24-0.60, respectively, with 1% cut-off and between 0.43-0.88 and 0.73-0.85, respectively, with 10% cut-off. For epithelium, 10% cut-off resulted in better estimates for both sensitivity and specificity. ICC between the cores was strongest for CD44 for both stroma and epithelium in normal TDLUs cores and benign lesions (range 0.74-0.80). ICC for CD24 and ALDH1A ranged between 0.42-0.63 and 0.44-0.55, respectively.
Our findings show that computational assessments for CD44, CD24, and ALDH1A1 exhibit variable correlations with manual assessment. These findings support the use of computational platforms for IHC evaluation of stem cell markers in large-scale epidemiologic studies. Pilot studies maybe also needed to determine appropriate cut-offs for defining staining positivity.
关于无癌女性乳腺组织中干细胞标志物CD44、CD24和ALDH1A1表达的数据非常有限,且此前尚无研究探讨病理学家与这些标志物的计算机评估之间的一致性。我们将一位专家病理学家对CD44、CD24和ALDH1A1的免疫组化(IHC)表达评估与自动图像分析结果进行了比较,并评估了每位女性多个样本芯中这些标志物的同质性。
我们纳入了护士健康研究(NHS)和NHSII队列中81名活检确诊为良性乳腺疾病的无癌女性(399个样本芯)。使用商用抗体进行免疫组化(CD44(美国加利福尼亚州圣克拉拉市达科公司),稀释度1:25;CD24(美国马萨诸塞州沃尔瑟姆市赛默飞世尔科技公司),稀释度1:200;ALDH1A1(英国剑桥市艾博抗公司),稀释度1:300)。对于每个样本芯,病理学家和Definiens Tissue Studio软件对阳性百分比进行量化。以病理学家的评分作为金标准,使用Spearman相关性(针对分类阳性:0、>0-<1、1-10、>10-50和>50%)和敏感性/特异性(针对以1%和10%为临界值定义的二元阳性)评估病理学家评分与计算机分析评分之间的相关性。使用组内相关性(ICC)检验表达同质性。分析按样本芯[正常终末导管小叶单位(TDLUs)、良性病变]和组织类型(上皮、间质)进行分层。
在正常TDLUs样本芯中,间质的病理学家评分与Definiens软件评分之间的Spearman相关性在0.40至0.64之间,上皮在0.66至0.68之间;在良性病变中,间质的相关性在0.24至0.60之间,上皮在0.61至0.64之间。对于间质,以1%为临界值时,敏感性和特异性分别在0.92至0.95和0.24至0.60之间;以10%为临界值时,分别在0.43至0.88和0.73至0.85之间。对于上皮,以10%为临界值时,敏感性和特异性的估计值更好。在正常TDLUs样本芯和良性病变中,间质和上皮中CD44的样本芯间ICC最强(范围为0.74至0.80)。CD24和ALDH1A的ICC分别在0.42至0.63和0.44至0.55之间。
我们的研究结果表明,CD44、CD24和ALDH1A1的计算机评估与手动评估之间存在不同程度的相关性。这些结果支持在大规模流行病学研究中使用计算机平台对干细胞标志物进行免疫组化评估。可能还需要开展试点研究以确定定义染色阳性的合适临界值。